2021年开始，神经介入领域被纳入集采，4年来行业格局已发生巨大变化。在集采政策的持续推动下，国产化率较低的器械领域成为了投资热点。今年以来，微创脑科学、归创通桥、沛嘉医疗-B涨幅分别达到72.77%、103.72%、113.32%。 市场最关注的，莫过于国产厂商的集采表现。归创通桥半年报显示，公司实现收入4.82亿元，同比增长31.7%，净利润1.21亿元，同比增长76%。近日，归创通桥管理层...
Source Link2021年开始，神经介入领域被纳入集采，4年来行业格局已发生巨大变化。在集采政策的持续推动下，国产化率较低的器械领域成为了投资热点。今年以来，微创脑科学、归创通桥、沛嘉医疗-B涨幅分别达到72.77%、103.72%、113.32%。 市场最关注的，莫过于国产厂商的集采表现。归创通桥半年报显示，公司实现收入4.82亿元，同比增长31.7%，净利润1.21亿元，同比增长76%。近日，归创通桥管理层...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.